Loading…

The Effect of AIDS Clinical Trials Group Protocol 5164 on the Time From Pneumocystis jirovecii Pneumonia Diagnosis to Antiretroviral Initiation in Routine Clinical Practice: A Case Study of Diffusion, Dissemination, and Implementation

Background. Diffusion, dissemination, and implementation of scientific evidence into routine clinical practice is not well understood. The Adult AIDS Clinical Trials Group (ACTG) Protocol 5164 showed that early antiretroviral therapy (ART; ie, within 14 days) after diagnosis of an opportunistic infe...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2011-11, Vol.53 (10), p.1008-1014
Main Authors: Geng, Elvin H., Kahn, James S., Chang, Olivia C., Hare, C. Bradley, Christopoulos, Katerina A., Jones, Diane, Petersen, Maya L., Deeks, Steven G., Havlir, Diane V., Gandhi, Monica
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c416t-99e06ec5fcac87e245e6c528683133c53c61c3a4caafbac131df669400a870083
cites cdi_FETCH-LOGICAL-c416t-99e06ec5fcac87e245e6c528683133c53c61c3a4caafbac131df669400a870083
container_end_page 1014
container_issue 10
container_start_page 1008
container_title Clinical infectious diseases
container_volume 53
creator Geng, Elvin H.
Kahn, James S.
Chang, Olivia C.
Hare, C. Bradley
Christopoulos, Katerina A.
Jones, Diane
Petersen, Maya L.
Deeks, Steven G.
Havlir, Diane V.
Gandhi, Monica
description Background. Diffusion, dissemination, and implementation of scientific evidence into routine clinical practice is not well understood. The Adult AIDS Clinical Trials Group (ACTG) Protocol 5164 showed that early antiretroviral therapy (ART; ie, within 14 days) after diagnosis of an opportunistic infection improved clinical outcomes, compared with later initiation. Subsequently, the San Francisco General Hospital (SFGH) HIV/AIDS Service performed the SFGH 5164 Initiative to disseminate and implement the findings of ACTG 5164. Methods. We evaluated patients who received a diagnosis of Pneumocystis jirovecii pneumonia (PCP) from 1 January 2001 through 30 March 2011. Survival analyses were used to assess changes in the time to initiation of ART after PCP, and logistic regression was used to evaluate changes in the odds of early ART (ie, within 14 days) because of ACTG 5164 and SFGH 5164 Initiative. Results. Among 162 patients, the adjusted hazard of ART initiation increased by 3.05 (95% confidence interval [CI], 1.86-5.02) after ACTG 5164 and by 4.89 (95% CI, 2.76-8.67) after the SFGH Initiative, compared with before ACTG 5164. When compared with before ACTG 5164, the proportion of patients who received ART within the 14 days after PCP diagnosis increased from 7.4% to 50.0% (P < .001) after ACTG 5164 and from 50.0% to 83.0% (P = .02) after the SFGH 5164 Initiative. Conclusions. Diffusion of findings from of a randomized trial changed practice at an academic medical center, but dissemination and implementation efforts were required to establish early ART at acceptable levels. Early ART initiation can be achieved in real-world patient populations.
doi_str_mv 10.1093/cid/cir608
format article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3193829</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>41328190</jstor_id><oup_id>10.1093/cid/cir608</oup_id><sourcerecordid>41328190</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-99e06ec5fcac87e245e6c528683133c53c61c3a4caafbac131df669400a870083</originalsourceid><addsrcrecordid>eNp9kkFvEzEQhVcIREvhwh1kISEk1IC93vXaHJCipC2RKhHRcF65E7udaNcOtrdS_jK_ArcJCXDgYNkaf37zRn5F8ZLRD4wq_hFwmVcQVD4qjlnNm5GoFXucz7SWo0pyeVQ8i3FFKWOS1k-Lo5IpQRtWHxc_F7eGnFlrIBFvyXg2vSKTDh2C7sgioO4iuQh-WJN58MmD70jNREW8Iym_XGBvyHnwPZk7M_QeNjFhJCsM_s4A4q7sUJMp6hvnY75NnoxdwmBSpjDkRjOHCXXCrIqOfPNDQmcOPuZBQ0Iwn8iYTHQ05CoNy8293ylaO8T87jQfYzQ9ugeZU6Ldksz6dWd649JD7XnxxOZxzIvdflJ8Pz9bTL6MLr9ezCbjyxFUTKSRUoYKA7UFDbIxZVUbAXUpheSMc6g5CAZcV6C1vdbAOFtaIVRFqZYNpZKfFJ-3uuvhujdLyP3zjO06YK_DpvUa279vHN62N_6u5UxxWaos8G4nEPyPwcTU9hjBdJ12xg-xlUrKigpBM_nmH3Llh-DydK2i2YsoyypD77cQBB9jMHZvhdH2PkBtDlC7DVCGX_9pfo_-TkwG3u4AHfPf2KAdYDxwVdNQRvmBy9n5f8NXW24Vkw97smK8lExR_gsiN-lR</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>900086224</pqid></control><display><type>article</type><title>The Effect of AIDS Clinical Trials Group Protocol 5164 on the Time From Pneumocystis jirovecii Pneumonia Diagnosis to Antiretroviral Initiation in Routine Clinical Practice: A Case Study of Diffusion, Dissemination, and Implementation</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Oxford Journals Online</source><creator>Geng, Elvin H. ; Kahn, James S. ; Chang, Olivia C. ; Hare, C. Bradley ; Christopoulos, Katerina A. ; Jones, Diane ; Petersen, Maya L. ; Deeks, Steven G. ; Havlir, Diane V. ; Gandhi, Monica</creator><creatorcontrib>Geng, Elvin H. ; Kahn, James S. ; Chang, Olivia C. ; Hare, C. Bradley ; Christopoulos, Katerina A. ; Jones, Diane ; Petersen, Maya L. ; Deeks, Steven G. ; Havlir, Diane V. ; Gandhi, Monica</creatorcontrib><description>Background. Diffusion, dissemination, and implementation of scientific evidence into routine clinical practice is not well understood. The Adult AIDS Clinical Trials Group (ACTG) Protocol 5164 showed that early antiretroviral therapy (ART; ie, within 14 days) after diagnosis of an opportunistic infection improved clinical outcomes, compared with later initiation. Subsequently, the San Francisco General Hospital (SFGH) HIV/AIDS Service performed the SFGH 5164 Initiative to disseminate and implement the findings of ACTG 5164. Methods. We evaluated patients who received a diagnosis of Pneumocystis jirovecii pneumonia (PCP) from 1 January 2001 through 30 March 2011. Survival analyses were used to assess changes in the time to initiation of ART after PCP, and logistic regression was used to evaluate changes in the odds of early ART (ie, within 14 days) because of ACTG 5164 and SFGH 5164 Initiative. Results. Among 162 patients, the adjusted hazard of ART initiation increased by 3.05 (95% confidence interval [CI], 1.86-5.02) after ACTG 5164 and by 4.89 (95% CI, 2.76-8.67) after the SFGH Initiative, compared with before ACTG 5164. When compared with before ACTG 5164, the proportion of patients who received ART within the 14 days after PCP diagnosis increased from 7.4% to 50.0% (P &lt; .001) after ACTG 5164 and from 50.0% to 83.0% (P = .02) after the SFGH 5164 Initiative. Conclusions. Diffusion of findings from of a randomized trial changed practice at an academic medical center, but dissemination and implementation efforts were required to establish early ART at acceptable levels. Early ART initiation can be achieved in real-world patient populations.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/cir608</identifier><identifier>PMID: 21960715</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Acquired immune deficiency syndrome ; Adult ; AIDS ; AIDS-Related Opportunistic Infections - diagnosis ; AIDS-Related Opportunistic Infections - etiology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral drugs ; Antiretroviral Therapy, Highly Active ; Antiretrovirals ; Antiviral agents ; Art periods ; Art therapy ; Biological and medical sciences ; Clinical trials ; Diffusion of Innovation ; Drug therapy ; Female ; HIV ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV/AIDS ; Human viral diseases ; Humans ; Infectious diseases ; Male ; Medical practice ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pneumocystis ; Pneumocystis carinii ; Pneumocystis pneumonia ; Pneumology ; Pneumonia ; Pneumonia, Pneumocystis - diagnosis ; Pneumonia, Pneumocystis - etiology ; Randomized Controlled Trials as Topic ; Respiratory system : syndromes and miscellaneous diseases ; Time Factors ; Treatment Outcome ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral Load</subject><ispartof>Clinical infectious diseases, 2011-11, Vol.53 (10), p.1008-1014</ispartof><rights>Copyright © 2011 Oxford University Press</rights><rights>The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. 2011</rights><rights>2015 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Nov 15, 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-99e06ec5fcac87e245e6c528683133c53c61c3a4caafbac131df669400a870083</citedby><cites>FETCH-LOGICAL-c416t-99e06ec5fcac87e245e6c528683133c53c61c3a4caafbac131df669400a870083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/41328190$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/41328190$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,778,782,883,27907,27908,58221,58454</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24770103$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21960715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geng, Elvin H.</creatorcontrib><creatorcontrib>Kahn, James S.</creatorcontrib><creatorcontrib>Chang, Olivia C.</creatorcontrib><creatorcontrib>Hare, C. Bradley</creatorcontrib><creatorcontrib>Christopoulos, Katerina A.</creatorcontrib><creatorcontrib>Jones, Diane</creatorcontrib><creatorcontrib>Petersen, Maya L.</creatorcontrib><creatorcontrib>Deeks, Steven G.</creatorcontrib><creatorcontrib>Havlir, Diane V.</creatorcontrib><creatorcontrib>Gandhi, Monica</creatorcontrib><title>The Effect of AIDS Clinical Trials Group Protocol 5164 on the Time From Pneumocystis jirovecii Pneumonia Diagnosis to Antiretroviral Initiation in Routine Clinical Practice: A Case Study of Diffusion, Dissemination, and Implementation</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Background. Diffusion, dissemination, and implementation of scientific evidence into routine clinical practice is not well understood. The Adult AIDS Clinical Trials Group (ACTG) Protocol 5164 showed that early antiretroviral therapy (ART; ie, within 14 days) after diagnosis of an opportunistic infection improved clinical outcomes, compared with later initiation. Subsequently, the San Francisco General Hospital (SFGH) HIV/AIDS Service performed the SFGH 5164 Initiative to disseminate and implement the findings of ACTG 5164. Methods. We evaluated patients who received a diagnosis of Pneumocystis jirovecii pneumonia (PCP) from 1 January 2001 through 30 March 2011. Survival analyses were used to assess changes in the time to initiation of ART after PCP, and logistic regression was used to evaluate changes in the odds of early ART (ie, within 14 days) because of ACTG 5164 and SFGH 5164 Initiative. Results. Among 162 patients, the adjusted hazard of ART initiation increased by 3.05 (95% confidence interval [CI], 1.86-5.02) after ACTG 5164 and by 4.89 (95% CI, 2.76-8.67) after the SFGH Initiative, compared with before ACTG 5164. When compared with before ACTG 5164, the proportion of patients who received ART within the 14 days after PCP diagnosis increased from 7.4% to 50.0% (P &lt; .001) after ACTG 5164 and from 50.0% to 83.0% (P = .02) after the SFGH 5164 Initiative. Conclusions. Diffusion of findings from of a randomized trial changed practice at an academic medical center, but dissemination and implementation efforts were required to establish early ART at acceptable levels. Early ART initiation can be achieved in real-world patient populations.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>AIDS</subject><subject>AIDS-Related Opportunistic Infections - diagnosis</subject><subject>AIDS-Related Opportunistic Infections - etiology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Antiretrovirals</subject><subject>Antiviral agents</subject><subject>Art periods</subject><subject>Art therapy</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Diffusion of Innovation</subject><subject>Drug therapy</subject><subject>Female</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV/AIDS</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical practice</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumocystis</subject><subject>Pneumocystis carinii</subject><subject>Pneumocystis pneumonia</subject><subject>Pneumology</subject><subject>Pneumonia</subject><subject>Pneumonia, Pneumocystis - diagnosis</subject><subject>Pneumonia, Pneumocystis - etiology</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Respiratory system : syndromes and miscellaneous diseases</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral Load</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9kkFvEzEQhVcIREvhwh1kISEk1IC93vXaHJCipC2RKhHRcF65E7udaNcOtrdS_jK_ArcJCXDgYNkaf37zRn5F8ZLRD4wq_hFwmVcQVD4qjlnNm5GoFXucz7SWo0pyeVQ8i3FFKWOS1k-Lo5IpQRtWHxc_F7eGnFlrIBFvyXg2vSKTDh2C7sgioO4iuQh-WJN58MmD70jNREW8Iym_XGBvyHnwPZk7M_QeNjFhJCsM_s4A4q7sUJMp6hvnY75NnoxdwmBSpjDkRjOHCXXCrIqOfPNDQmcOPuZBQ0Iwn8iYTHQ05CoNy8293ylaO8T87jQfYzQ9ugeZU6Ldksz6dWd649JD7XnxxOZxzIvdflJ8Pz9bTL6MLr9ezCbjyxFUTKSRUoYKA7UFDbIxZVUbAXUpheSMc6g5CAZcV6C1vdbAOFtaIVRFqZYNpZKfFJ-3uuvhujdLyP3zjO06YK_DpvUa279vHN62N_6u5UxxWaos8G4nEPyPwcTU9hjBdJ12xg-xlUrKigpBM_nmH3Llh-DydK2i2YsoyypD77cQBB9jMHZvhdH2PkBtDlC7DVCGX_9pfo_-TkwG3u4AHfPf2KAdYDxwVdNQRvmBy9n5f8NXW24Vkw97smK8lExR_gsiN-lR</recordid><startdate>20111115</startdate><enddate>20111115</enddate><creator>Geng, Elvin H.</creator><creator>Kahn, James S.</creator><creator>Chang, Olivia C.</creator><creator>Hare, C. Bradley</creator><creator>Christopoulos, Katerina A.</creator><creator>Jones, Diane</creator><creator>Petersen, Maya L.</creator><creator>Deeks, Steven G.</creator><creator>Havlir, Diane V.</creator><creator>Gandhi, Monica</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20111115</creationdate><title>The Effect of AIDS Clinical Trials Group Protocol 5164 on the Time From Pneumocystis jirovecii Pneumonia Diagnosis to Antiretroviral Initiation in Routine Clinical Practice: A Case Study of Diffusion, Dissemination, and Implementation</title><author>Geng, Elvin H. ; Kahn, James S. ; Chang, Olivia C. ; Hare, C. Bradley ; Christopoulos, Katerina A. ; Jones, Diane ; Petersen, Maya L. ; Deeks, Steven G. ; Havlir, Diane V. ; Gandhi, Monica</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-99e06ec5fcac87e245e6c528683133c53c61c3a4caafbac131df669400a870083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>AIDS</topic><topic>AIDS-Related Opportunistic Infections - diagnosis</topic><topic>AIDS-Related Opportunistic Infections - etiology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Antiretrovirals</topic><topic>Antiviral agents</topic><topic>Art periods</topic><topic>Art therapy</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Diffusion of Innovation</topic><topic>Drug therapy</topic><topic>Female</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV/AIDS</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical practice</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumocystis</topic><topic>Pneumocystis carinii</topic><topic>Pneumocystis pneumonia</topic><topic>Pneumology</topic><topic>Pneumonia</topic><topic>Pneumonia, Pneumocystis - diagnosis</topic><topic>Pneumonia, Pneumocystis - etiology</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Respiratory system : syndromes and miscellaneous diseases</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geng, Elvin H.</creatorcontrib><creatorcontrib>Kahn, James S.</creatorcontrib><creatorcontrib>Chang, Olivia C.</creatorcontrib><creatorcontrib>Hare, C. Bradley</creatorcontrib><creatorcontrib>Christopoulos, Katerina A.</creatorcontrib><creatorcontrib>Jones, Diane</creatorcontrib><creatorcontrib>Petersen, Maya L.</creatorcontrib><creatorcontrib>Deeks, Steven G.</creatorcontrib><creatorcontrib>Havlir, Diane V.</creatorcontrib><creatorcontrib>Gandhi, Monica</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geng, Elvin H.</au><au>Kahn, James S.</au><au>Chang, Olivia C.</au><au>Hare, C. Bradley</au><au>Christopoulos, Katerina A.</au><au>Jones, Diane</au><au>Petersen, Maya L.</au><au>Deeks, Steven G.</au><au>Havlir, Diane V.</au><au>Gandhi, Monica</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effect of AIDS Clinical Trials Group Protocol 5164 on the Time From Pneumocystis jirovecii Pneumonia Diagnosis to Antiretroviral Initiation in Routine Clinical Practice: A Case Study of Diffusion, Dissemination, and Implementation</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2011-11-15</date><risdate>2011</risdate><volume>53</volume><issue>10</issue><spage>1008</spage><epage>1014</epage><pages>1008-1014</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>Background. Diffusion, dissemination, and implementation of scientific evidence into routine clinical practice is not well understood. The Adult AIDS Clinical Trials Group (ACTG) Protocol 5164 showed that early antiretroviral therapy (ART; ie, within 14 days) after diagnosis of an opportunistic infection improved clinical outcomes, compared with later initiation. Subsequently, the San Francisco General Hospital (SFGH) HIV/AIDS Service performed the SFGH 5164 Initiative to disseminate and implement the findings of ACTG 5164. Methods. We evaluated patients who received a diagnosis of Pneumocystis jirovecii pneumonia (PCP) from 1 January 2001 through 30 March 2011. Survival analyses were used to assess changes in the time to initiation of ART after PCP, and logistic regression was used to evaluate changes in the odds of early ART (ie, within 14 days) because of ACTG 5164 and SFGH 5164 Initiative. Results. Among 162 patients, the adjusted hazard of ART initiation increased by 3.05 (95% confidence interval [CI], 1.86-5.02) after ACTG 5164 and by 4.89 (95% CI, 2.76-8.67) after the SFGH Initiative, compared with before ACTG 5164. When compared with before ACTG 5164, the proportion of patients who received ART within the 14 days after PCP diagnosis increased from 7.4% to 50.0% (P &lt; .001) after ACTG 5164 and from 50.0% to 83.0% (P = .02) after the SFGH 5164 Initiative. Conclusions. Diffusion of findings from of a randomized trial changed practice at an academic medical center, but dissemination and implementation efforts were required to establish early ART at acceptable levels. Early ART initiation can be achieved in real-world patient populations.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>21960715</pmid><doi>10.1093/cid/cir608</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2011-11, Vol.53 (10), p.1008-1014
issn 1058-4838
1537-6591
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3193829
source JSTOR Archival Journals and Primary Sources Collection; Oxford Journals Online
subjects Acquired immune deficiency syndrome
Adult
AIDS
AIDS-Related Opportunistic Infections - diagnosis
AIDS-Related Opportunistic Infections - etiology
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiretroviral drugs
Antiretroviral Therapy, Highly Active
Antiretrovirals
Antiviral agents
Art periods
Art therapy
Biological and medical sciences
Clinical trials
Diffusion of Innovation
Drug therapy
Female
HIV
HIV Infections - complications
HIV Infections - drug therapy
HIV/AIDS
Human viral diseases
Humans
Infectious diseases
Male
Medical practice
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pneumocystis
Pneumocystis carinii
Pneumocystis pneumonia
Pneumology
Pneumonia
Pneumonia, Pneumocystis - diagnosis
Pneumonia, Pneumocystis - etiology
Randomized Controlled Trials as Topic
Respiratory system : syndromes and miscellaneous diseases
Time Factors
Treatment Outcome
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral Load
title The Effect of AIDS Clinical Trials Group Protocol 5164 on the Time From Pneumocystis jirovecii Pneumonia Diagnosis to Antiretroviral Initiation in Routine Clinical Practice: A Case Study of Diffusion, Dissemination, and Implementation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A19%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effect%20of%20AIDS%20Clinical%20Trials%20Group%20Protocol%205164%20on%20the%20Time%20From%20Pneumocystis%20jirovecii%20Pneumonia%20Diagnosis%20to%20Antiretroviral%20Initiation%20in%20Routine%20Clinical%20Practice:%20A%20Case%20Study%20of%20Diffusion,%20Dissemination,%20and%20Implementation&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Geng,%20Elvin%20H.&rft.date=2011-11-15&rft.volume=53&rft.issue=10&rft.spage=1008&rft.epage=1014&rft.pages=1008-1014&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1093/cid/cir608&rft_dat=%3Cjstor_pubme%3E41328190%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c416t-99e06ec5fcac87e245e6c528683133c53c61c3a4caafbac131df669400a870083%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=900086224&rft_id=info:pmid/21960715&rft_jstor_id=41328190&rft_oup_id=10.1093/cid/cir608&rfr_iscdi=true